Selective Genetics/Spinal Concepts
This article was originally published in The Gray Sheet
Executive Summary
Selective will receive up to $12 mil. from Spinal Concepts in equity purchases, license fees, R&D support or milestone payments, plus a royalty on sales, under a joint development program. The program will combine Selective's GAM gene-activated matrices with Spinal Concepts' InFix and other interbody fusion devices. Under the terms of the deal, Spinal Concepts will receive a worldwide, co-exclusive license for the use of GAM with interbody devices and will market the combined product. Selective will manufacture the GAM